Botox and asthma seem like an unlikely pair. One paralyzes muscles and removes wrinkles, while the other restricts air flow. It doesn't seem like paralysis would be useful in letting more air through, but that's exactly the hypothesis put forth by Professor Philip Bardin of Australia's Monash Medical Centre.
In some forms of asthma, not only is air flow restricted within the lungs, but the vocal cords also spasm and prevent air from flowing freely through them. Bardin said the phenomenon was "like breathing through a straw," as reported by the Sydney Morning Herald.
The research study hopes to solve this problem by injecting botulinum toxin, more commonly known by the trade name "Botox," directly into the vocal cords, which will prevent them from going into spasms. This treatment is already used for laryngeal dystonia, where the vocal cords involuntarily contract. People can still speak after the treatment, but their voices are softer than normal.
According to the US Dept of Health and Human services, over 20 million Americans currently have asthma and 7.7 million Americans reported having an asthma attack in the last 12 months.
While asthma cases involve restricted airflow through the lungs, some of them involve both the lungs and vocal cords. The vocal cord treatment with Botox could help transform severe cases of asthma into ones that can be more easily managed.
The FDA approved use of botulinum toxin for cosmetic purposes in 2002 and it has since become widely used to reduce wrinkles and facial frown lines. Its medical uses included treatment of muscular pain disorders.
Jumat, 01 Juli 2011
Botox Treatment May Assist Asthmatics
Researchers in Australia believe that a Botox injection, which has been widely used in recent years for cosmetic purposes, could also hold the key to treating people who suffer from severe asthma.
Since 2002, when the United States Food and Drug Administration approved Botox for cosmetic purposes, the injection has been used to reduce facial frown lines and wrinkles.
However, Botox, also known as botulinum toxin, also has a number of medical uses, including treatment of muscular pain disorders. The botulinum toxin is used for medical and cosmetic purposes because of its ability to paralyze and relax skin and muscles.
While the drug has already been successful in treating some vocal cord disorders, such as largyngael dystonia, which is characterized by an involuntary contraction of the vocal cords, it has yet to be proven as an effective treatment for asthmatics.
However, Professor Philip Bardin of Australia’s Monash Medical Centre believes that Botox could be directly injected into the vocal cords, which would prevent them from going into spasms during an asthma attack.
“We don’t think this will cure these asthmatics but it will help them to live better with asthma”, Mr. Bardin said.
If his hypothesis is correct, this new treatment would be able to relieve nearly 250,000 people living with severe asthma in Australia.
Since 2002, when the United States Food and Drug Administration approved Botox for cosmetic purposes, the injection has been used to reduce facial frown lines and wrinkles.
However, Botox, also known as botulinum toxin, also has a number of medical uses, including treatment of muscular pain disorders. The botulinum toxin is used for medical and cosmetic purposes because of its ability to paralyze and relax skin and muscles.
While the drug has already been successful in treating some vocal cord disorders, such as largyngael dystonia, which is characterized by an involuntary contraction of the vocal cords, it has yet to be proven as an effective treatment for asthmatics.
However, Professor Philip Bardin of Australia’s Monash Medical Centre believes that Botox could be directly injected into the vocal cords, which would prevent them from going into spasms during an asthma attack.
“We don’t think this will cure these asthmatics but it will help them to live better with asthma”, Mr. Bardin said.
If his hypothesis is correct, this new treatment would be able to relieve nearly 250,000 people living with severe asthma in Australia.
Asthma Patients May Rely on Botox in Future, Say Researchers
Botox injections which are famous for cosmetic surgery can be used for the treatment of the asthma patients as well.
The physicians will be curing the asthma patients now by injecting botox in the larynx to loosen up their muscle contractions, which will assist in breathing troubles, said the researchers of Melbourne’s Monash University.
The researchers are testing on the Botulinum toxin type A to confirm that whether it can provide any support to the asthma suffers.
Professor Phil Bardin, one of the researchers, stated that though it is not going to cure the disease but, it will help the asthmatic patients to live in a better way.
"The rationale for this is that we think that the muscles in voice box have become dysfunctional and have fallen into bad habits as part of the asthmatic process and may be compensating for the lung", he said.
US Department of Health and Human Services had notified that over 20 million Americans are suffering from asthmatic problems and around 7.7 million Americans notified of the asthma attack in recent 12 months.
With Botox name in the treatment list will earn respect to the drug as it is quite amazing to know that the drug can actually be a solution in healing the asthma problem to an extent.
The physicians will be curing the asthma patients now by injecting botox in the larynx to loosen up their muscle contractions, which will assist in breathing troubles, said the researchers of Melbourne’s Monash University.
The researchers are testing on the Botulinum toxin type A to confirm that whether it can provide any support to the asthma suffers.
Professor Phil Bardin, one of the researchers, stated that though it is not going to cure the disease but, it will help the asthmatic patients to live in a better way.
"The rationale for this is that we think that the muscles in voice box have become dysfunctional and have fallen into bad habits as part of the asthmatic process and may be compensating for the lung", he said.
US Department of Health and Human Services had notified that over 20 million Americans are suffering from asthmatic problems and around 7.7 million Americans notified of the asthma attack in recent 12 months.
With Botox name in the treatment list will earn respect to the drug as it is quite amazing to know that the drug can actually be a solution in healing the asthma problem to an extent.
Botox may help with some cases of asthma
Researchers at the Monash Medical Centre in Australia will be testing asthma patients with a novel form of treatment for asthma: the wrinkle-smoothing agent Botox. The theory behind the treatment is that the Botox will relax the muscles of the voice box, making it easier for some asthma patients to breathe.
Botox has already been used to treat some forms of vocal chord dysfunction, such as abnormal, involuntary movements of the voice box. It is still not clear whether patients with voice box problems and people with asthma will respond to the treatment in a similar fashion, but the way the voice box malfunctions is similar in both conditions. Both have similar symptoms.
About 20 to 60% of asthma patients have voice box problems, and this is the segment of asthma sufferers which might potentially benefit from the treatment the most.
“It's not clear why asthma might predispose someone to also having vocal cord problems, but vocal cord problems make asthma symptoms worse,” said Dr. Shirin Shafazand, an assistant professor of medicine at the University of Miami Miller School of Medicine.
The voice box is a door to the windpipe. If it is malfunctioning, the condition results in breathing difficulties. Studies have shown those with asthma and voice box problems perceive their symptoms as more severe, Shafazand said. Voice box problems might also trigger an asthma attack. Since an asthma attack can be precipitated by stress, someone having problems breathing because of voice box spasms may experience anxiety and set off their asthma.
The active ingredient in Botox is botulinum toxin, a protein produced by the bacteria Clostridium botulinum. The drug is thought to work by blocking nerve signals to the muscles, thus relaxing them. Clearly, researchers will need to be careful in how they apply their treatment to the voice box, as it can potentially paralyze it.
It is also important to realize that even if it works, the Botox cannot treat the underlying asthma, which is an inflammatory response of the airways in the lungs. The inflammation narrows them, thereby causing difficulties in oxygen exchange. Botox treatment would only apply to the voice box and would serve only the subpopulation of asthma sufferers who also experience voice box difficulties.
It might make the asthma attacks more tolerable or less scary, but the inflammatory response awaits treatment by different medications.
Botox has already been used to treat some forms of vocal chord dysfunction, such as abnormal, involuntary movements of the voice box. It is still not clear whether patients with voice box problems and people with asthma will respond to the treatment in a similar fashion, but the way the voice box malfunctions is similar in both conditions. Both have similar symptoms.
About 20 to 60% of asthma patients have voice box problems, and this is the segment of asthma sufferers which might potentially benefit from the treatment the most.
“It's not clear why asthma might predispose someone to also having vocal cord problems, but vocal cord problems make asthma symptoms worse,” said Dr. Shirin Shafazand, an assistant professor of medicine at the University of Miami Miller School of Medicine.
The voice box is a door to the windpipe. If it is malfunctioning, the condition results in breathing difficulties. Studies have shown those with asthma and voice box problems perceive their symptoms as more severe, Shafazand said. Voice box problems might also trigger an asthma attack. Since an asthma attack can be precipitated by stress, someone having problems breathing because of voice box spasms may experience anxiety and set off their asthma.
The active ingredient in Botox is botulinum toxin, a protein produced by the bacteria Clostridium botulinum. The drug is thought to work by blocking nerve signals to the muscles, thus relaxing them. Clearly, researchers will need to be careful in how they apply their treatment to the voice box, as it can potentially paralyze it.
It is also important to realize that even if it works, the Botox cannot treat the underlying asthma, which is an inflammatory response of the airways in the lungs. The inflammation narrows them, thereby causing difficulties in oxygen exchange. Botox treatment would only apply to the voice box and would serve only the subpopulation of asthma sufferers who also experience voice box difficulties.
It might make the asthma attacks more tolerable or less scary, but the inflammatory response awaits treatment by different medications.
Botox may help folks with asthma breathe easier
The drug will be tested on asthmatic patients who also suffer problems with their voice box, which can go into spasm, according to Monash Medical Centre in Australia. The idea is that the Botox will relax the muscle that controls the voice box, possibly making it easier for these patients to breathe.
“It’s the first time in the world that there has been such a new approach to a very difficult problem," said Peter Holmes, a researcher at the center.
Botox has been used in some cases to treat people who suffer from vocal cord dysfunction, a condition characterized by abnormal movement of the voice box muscle, said Dr. John Mastronarde, director of the Ohio State Asthma Center.
"It's interesting and certainly has some potential to help people," Mastronarde said of the new study, but added it's not clear that patients with asthma and voice box problems would respond in the same way to the treatment, so its important to test it first.
People with vocal cord dysfunction and people with asthma have similar symptoms, so it can be hard to distinguish between the two, Mastronarde said. Somewhere between 20 and 60 percent of asthma patients have been found to also have vocal cord problems, he said.
It's not clear why asthma might predispose someone to also having vocal cord problems, but vocal cord problems make asthma symptoms worse, said Dr. Shirin Shafazand, an assistant professor of medicine at the University of Miami Miller School of Medicine.
The voice box can be thought of as a door to the windpipe, Shafazand told MyHealthNewsDaily. And if that door isn't working properly, or is closed when it should be open, a patient would have problems breathing, she said.
Studies have shown those with asthma and voice box problems perceive their symptoms as more severe, Shafazand said.
Voice box problems might also trigger asthma symptoms, Mastronarde said. Stress is known to exacerbate asthma symptoms. If someone is having problems breathing because of voice box spasms, they may experience anxiety and set off their asthma. "You can get into a vicious cycle," Mastronarde said.
Botox contains botulinum toxin, a protein produced by the bacteria Clostridium botulinum. The drug is thought to work by blocking nerve signals to the muscles, thus relaxing them.
The drug is a toxin, and the researchers need to be careful they don't paralyze the voice box muscles completely, Shafazand said, a risk she said she is sure the researchers are aware of.
It remains to be seen whether this treatment will work, Shafazand said. Even if it does work, she added, it will not treat the underlying asthma, which arises when airways to the lungs become inflamed or narrowed, resulting in breathlessness, wheezing and coughing.
“It’s the first time in the world that there has been such a new approach to a very difficult problem," said Peter Holmes, a researcher at the center.
Botox has been used in some cases to treat people who suffer from vocal cord dysfunction, a condition characterized by abnormal movement of the voice box muscle, said Dr. John Mastronarde, director of the Ohio State Asthma Center.
"It's interesting and certainly has some potential to help people," Mastronarde said of the new study, but added it's not clear that patients with asthma and voice box problems would respond in the same way to the treatment, so its important to test it first.
People with vocal cord dysfunction and people with asthma have similar symptoms, so it can be hard to distinguish between the two, Mastronarde said. Somewhere between 20 and 60 percent of asthma patients have been found to also have vocal cord problems, he said.
It's not clear why asthma might predispose someone to also having vocal cord problems, but vocal cord problems make asthma symptoms worse, said Dr. Shirin Shafazand, an assistant professor of medicine at the University of Miami Miller School of Medicine.
The voice box can be thought of as a door to the windpipe, Shafazand told MyHealthNewsDaily. And if that door isn't working properly, or is closed when it should be open, a patient would have problems breathing, she said.
Studies have shown those with asthma and voice box problems perceive their symptoms as more severe, Shafazand said.
Voice box problems might also trigger asthma symptoms, Mastronarde said. Stress is known to exacerbate asthma symptoms. If someone is having problems breathing because of voice box spasms, they may experience anxiety and set off their asthma. "You can get into a vicious cycle," Mastronarde said.
Botox contains botulinum toxin, a protein produced by the bacteria Clostridium botulinum. The drug is thought to work by blocking nerve signals to the muscles, thus relaxing them.
The drug is a toxin, and the researchers need to be careful they don't paralyze the voice box muscles completely, Shafazand said, a risk she said she is sure the researchers are aware of.
It remains to be seen whether this treatment will work, Shafazand said. Even if it does work, she added, it will not treat the underlying asthma, which arises when airways to the lungs become inflamed or narrowed, resulting in breathlessness, wheezing and coughing.
Rabu, 29 Juni 2011
Dysport Rebate: To Take on Botox and Look Younger, Rival Tries Rebate
Allergan and Medicis Pharmaceutical are the Coke and Pepsi of vanity medicine. Allergan makes Botox Cosmetic, the well-known injectable anti-wrinkle treatment. Medicis markets Dysport, a competing anti-wrinkle shot, in the United States. The Food and Drug Administration has approved both drugs to smooth skin furrows between the eyebrows.
And now Medicis has introduced a new marketing campaign that pits Dysport directly against Botox, essentially issuing a Pepsi challenge for the wrinkle wars. The campaign is even called the Dysport challenge.
Medicis is offering more than rebates on its own product. For customers who feel unsatisfied after trying Dysport, the company is also offering a rebate on a treatment with Allergan’s Botox.
“We are so confident that we are literally willing to bet our money that patients will love their Dysport treatment,” said Jonah Shacknai, the chief executive of Medicis.
The Dysport campaign, which runs through April 30, is thought to be the first time a drug maker has offered a rebate on a competing drug. But it is hardly the first instance of pushing pharmaceuticals with a marketing zeal more typical of consumer products that do not carry a risk of medical side effects.
These days, hoping to inspire patient loyalty, various makers of prescription drugs are promoting giveaways, rebates and discounts. Sepracor, for instance, is offering a seven-day free trial of its popular sleeping pill Lunesta. Merck is running a print ad with a voucher for a free 30-day supply of its Januvia tablets for Type 2 diabetes. Another Merck ad carries a $20 coupon for the allergy and asthma drug Singulair.
But it is vanity medicine — including products like Botox and Dysport — that has been at the forefront of consumer enticement programs. That is because insurance typically does not cover such medical products, meaning consumers must pay for them out of pocket, buying directly from physicians. Volume discounts or rebates for the doctors have also been part of the marketing push.
Some medical ethicists worry that the discounts and deals may prompt doctors and patients to make decisions based on money rather than efficacy and safety. When doctors sell cosmetic medical treatments on which they themselves receive rebates, it poses inherent conflicts of interest, said Dr. Carl Elliott, a professor of bioethics at the University of Minnesota medical school
“It’s like a doctor who has his own drugstore, and he’s writing the prescriptions and selling them,” Dr. Elliott said. “It’s the treatment of medicine as a consumer product that seems a little creepy.”
Neither Botox nor Dysport is entirely risk-free. Both are purified forms of botulinum toxin — a nerve poison produced by the bacteria that can cause botulism. The injections have occasionally resulted in temporary cosmetic problems like droopy eyelids or uneven eyebrows. And such drugs now display federally mandated “black box” warnings on their labels stating that botulinum toxins have been associated with rare but potentially life-threatening health problems.
Mr. Shacknai of Medicis said he understood ethicists’ concerns about the marketing of medications prescribed to treat specific diseases. But Dysport and Restylane, a skin-plumping injection marketed by Medicis, are not disease treatments, he said, but cosmetic products intended to improve the appearance.
“What we are doing with the Dysport challenge and ongoing promotions for Restylane,” he said, “is to make it easier financially for people to try our products after consulting with a physician and determining if it’s right for them.”
The Dysport promotion, running on the product’s Web site and in a few glossy magazines like Us Weekly, offers a $75 rebate check on an initial Dysport treatment for wrinkles between the eyebrows, a procedure that can cost consumers $300 to $500.
The “challenge” comes into play for those who elect to have a second procedure three months later. Satisfied customers can receive a $75 rebate on a follow-up Dysport treatment, while dissatisfied customers who want to switch can receive a $75 rebate on a Botox treatment.
“This is really a novel spin,” said Dr. Kenneth Beer, a dermatologist in West Palm Beach, Fla., who is a paid investigator, consultant and speaker for both Allergan and Medicis. “There are always loyalty or affinity rebates, but they never come in and say, ‘Check out the neighborhood and, if you don’t like it, we’ll pay you to move back.’ ”
The campaign demonstrates the lengths to which a new entrant to the wrinkle-smoother category will go to gain market share from Botox, which enjoyed a virtual monopoly on injectable toxins in the United States until the introduction of Dysport last year.
Botox, a drug that has both cosmetic and medical uses, had worldwide sales last year of about $1.3 billion. Gary Nachman, an analyst at the health care investment bank Leerink Swann, estimated that Dysport could eventually gain a 20 to 25 percent market share in the United States. He described the Dysport rebate effort as a kind of “Hail Mary pass” that could help Medicis get to that point faster.
Last month, Medicis sent out a mass message about the rebate to its physician customers.
“Financially speaking, there’s no reason not to try Dysport,” said the Medicis message. “This offer is so unique that we expect plenty of news coverage. And we have promotional items for use in your office.”
Caroline Van Hove, an Allergan spokeswoman, responded to a reporter’s query with an e-mail message that described the Dysport promotion as a price-cutting exercise meant to cannibalize the market — at the expense of patient education. She wrote that “incentive programs like Medicis’s engage consumers for the wrong reasons, deflecting their attention to bargain shopping versus proper physician dialogue on product benefits/safety.”
Mr. Shacknai of Medicis said the Dysport promotion “understandably would create fear and concern with our competitors” because the rebate could lead to a significant shift in market share.
Drug advertising is often expensive. But given the economics, the Dysport rebate promotion is not sustainable for long, said Ronny Gal, an analyst at the research firm Sanford C. Bernstein & Company.
With a list price to physicians of $475 per vial — enough to treat the eyebrow furrows of perhaps five patients — Dysport brings Medicis about $100 per treatment, he said, so a $75 rebate for each is steep. Moreover, the rebate program effectively repositions Dysport as a value brand, a risky strategy in the luxury sector of vanity medicine, Mr. Gal said.
In any case, critics like Dr. Elliott of Minnesota say this latest wrinkle in the wrinkle wars pushes drug marketing one step further away from evidence-based medicine and deeper into the realm of product promotion.
“I’m not fan of turning medicine into a consumer product,” Dr. Elliot said. “But we are so far into it already that I don’t see the tide turning back.”
Medicis is offering more than rebates on its own product. For customers who feel unsatisfied after trying Dysport, the company is also offering a rebate on a treatment with Allergan’s Botox.
“We are so confident that we are literally willing to bet our money that patients will love their Dysport treatment,” said Jonah Shacknai, the chief executive of Medicis.
The Dysport campaign, which runs through April 30, is thought to be the first time a drug maker has offered a rebate on a competing drug. But it is hardly the first instance of pushing pharmaceuticals with a marketing zeal more typical of consumer products that do not carry a risk of medical side effects.
These days, hoping to inspire patient loyalty, various makers of prescription drugs are promoting giveaways, rebates and discounts. Sepracor, for instance, is offering a seven-day free trial of its popular sleeping pill Lunesta. Merck is running a print ad with a voucher for a free 30-day supply of its Januvia tablets for Type 2 diabetes. Another Merck ad carries a $20 coupon for the allergy and asthma drug Singulair.
But it is vanity medicine — including products like Botox and Dysport — that has been at the forefront of consumer enticement programs. That is because insurance typically does not cover such medical products, meaning consumers must pay for them out of pocket, buying directly from physicians. Volume discounts or rebates for the doctors have also been part of the marketing push.
Some medical ethicists worry that the discounts and deals may prompt doctors and patients to make decisions based on money rather than efficacy and safety. When doctors sell cosmetic medical treatments on which they themselves receive rebates, it poses inherent conflicts of interest, said Dr. Carl Elliott, a professor of bioethics at the University of Minnesota medical school
“It’s like a doctor who has his own drugstore, and he’s writing the prescriptions and selling them,” Dr. Elliott said. “It’s the treatment of medicine as a consumer product that seems a little creepy.”
Neither Botox nor Dysport is entirely risk-free. Both are purified forms of botulinum toxin — a nerve poison produced by the bacteria that can cause botulism. The injections have occasionally resulted in temporary cosmetic problems like droopy eyelids or uneven eyebrows. And such drugs now display federally mandated “black box” warnings on their labels stating that botulinum toxins have been associated with rare but potentially life-threatening health problems.
Mr. Shacknai of Medicis said he understood ethicists’ concerns about the marketing of medications prescribed to treat specific diseases. But Dysport and Restylane, a skin-plumping injection marketed by Medicis, are not disease treatments, he said, but cosmetic products intended to improve the appearance.
“What we are doing with the Dysport challenge and ongoing promotions for Restylane,” he said, “is to make it easier financially for people to try our products after consulting with a physician and determining if it’s right for them.”
The Dysport promotion, running on the product’s Web site and in a few glossy magazines like Us Weekly, offers a $75 rebate check on an initial Dysport treatment for wrinkles between the eyebrows, a procedure that can cost consumers $300 to $500.
The “challenge” comes into play for those who elect to have a second procedure three months later. Satisfied customers can receive a $75 rebate on a follow-up Dysport treatment, while dissatisfied customers who want to switch can receive a $75 rebate on a Botox treatment.
“This is really a novel spin,” said Dr. Kenneth Beer, a dermatologist in West Palm Beach, Fla., who is a paid investigator, consultant and speaker for both Allergan and Medicis. “There are always loyalty or affinity rebates, but they never come in and say, ‘Check out the neighborhood and, if you don’t like it, we’ll pay you to move back.’ ”
The campaign demonstrates the lengths to which a new entrant to the wrinkle-smoother category will go to gain market share from Botox, which enjoyed a virtual monopoly on injectable toxins in the United States until the introduction of Dysport last year.
Botox, a drug that has both cosmetic and medical uses, had worldwide sales last year of about $1.3 billion. Gary Nachman, an analyst at the health care investment bank Leerink Swann, estimated that Dysport could eventually gain a 20 to 25 percent market share in the United States. He described the Dysport rebate effort as a kind of “Hail Mary pass” that could help Medicis get to that point faster.
Last month, Medicis sent out a mass message about the rebate to its physician customers.
“Financially speaking, there’s no reason not to try Dysport,” said the Medicis message. “This offer is so unique that we expect plenty of news coverage. And we have promotional items for use in your office.”
Caroline Van Hove, an Allergan spokeswoman, responded to a reporter’s query with an e-mail message that described the Dysport promotion as a price-cutting exercise meant to cannibalize the market — at the expense of patient education. She wrote that “incentive programs like Medicis’s engage consumers for the wrong reasons, deflecting their attention to bargain shopping versus proper physician dialogue on product benefits/safety.”
Mr. Shacknai of Medicis said the Dysport promotion “understandably would create fear and concern with our competitors” because the rebate could lead to a significant shift in market share.
Drug advertising is often expensive. But given the economics, the Dysport rebate promotion is not sustainable for long, said Ronny Gal, an analyst at the research firm Sanford C. Bernstein & Company.
With a list price to physicians of $475 per vial — enough to treat the eyebrow furrows of perhaps five patients — Dysport brings Medicis about $100 per treatment, he said, so a $75 rebate for each is steep. Moreover, the rebate program effectively repositions Dysport as a value brand, a risky strategy in the luxury sector of vanity medicine, Mr. Gal said.
In any case, critics like Dr. Elliott of Minnesota say this latest wrinkle in the wrinkle wars pushes drug marketing one step further away from evidence-based medicine and deeper into the realm of product promotion.
“I’m not fan of turning medicine into a consumer product,” Dr. Elliot said. “But we are so far into it already that I don’t see the tide turning back.”
Botox Hoax : Mom at center of Botox hoax now in counseling |
The infamous ‘Botox Mom’ or Botok Hoax that was at the center of so much scandal a few months ago is making news again, but not for subjecting her daughter to painful injections for the sake of child beauty pageants. mother botox daughter Instead, it is because of her efforts to be a better mother.
To regain custody of her two daughters, Botox Hoax is undergoing mental health counseling. Thankfully, she's taking parenting classes, according to an exclusive with Radar Online. She will be evaluated for about six months.
At first known as Kerry Campbell, but later revealed to be named Sheena Upton, she once went on Good Morning America to talk about her immediately controversial story – and they refused to pay her $10 thousand dollars for appearing on the program (when she claimed to have only made $200 for originally appearing in UK paper The Sun).
Why did she get stiffed? In a taped interview with TMZ, Upton claimed that the original interview and accompanying photos were scripted. But she never had much of an explanation about why she continued to support the lie, or why she went on so many chat shows to discuss the story – which may be the reason behind the counseling.
There has been no information regarding how Upton’s daughters have been dealing with the scandal, or if they have undergone any family counseling.
At first known as Kerry Campbell, but later revealed to be named Sheena Upton, she once went on Good Morning America to talk about her immediately controversial story – and they refused to pay her $10 thousand dollars for appearing on the program (when she claimed to have only made $200 for originally appearing in UK paper The Sun).
Why did she get stiffed? In a taped interview with TMZ, Upton claimed that the original interview and accompanying photos were scripted. But she never had much of an explanation about why she continued to support the lie, or why she went on so many chat shows to discuss the story – which may be the reason behind the counseling.
There has been no information regarding how Upton’s daughters have been dealing with the scandal, or if they have undergone any family counseling.
Langganan:
Postingan (Atom)